MARKET

AZRX

AZRX

AzurRx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.500
+0.060
+4.17%
Pre Market: 1.430 -0.07 -4.67% 05:53 03/02 EST
OPEN
1.500
PREV CLOSE
1.440
HIGH
1.520
LOW
1.450
VOLUME
151
TURNOVER
--
52 WEEK HIGH
2.630
52 WEEK LOW
0.3709
MARKET CAP
80.13M
P/E (TTM)
-1.6976
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
8-K: AzurRx BioPharma, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
Pandion Therapeutics, Dynatronics leads healthcare gainers; U.S. Physical Therapy, CollPlant Biotechnologies among major losers
Gainers: Pandion Therapeutics (PAND) +132%, Dynatronics (DYNT) +68%, ChromaDex (CDXC) +30%, ASLAN Pharmaceuticals (ASLN) +28%, Brookdale Senior Living (BKD) +22%.Losers: U.S. Physical Therapy (USPH) -21%, CollPlant Biotechnologies (CLGN) -21%, Akebia Thera...
Seekingalpha · 4d ago
5 Hot Penny Stocks Analysts Rate A Buy Right Now But Do You Agree?
Feb 24, 2021 (Penny Stocks via COMTEX) -- Hot Penny Stocks To Buy According To These Analysts Are you looking for penny stocks to buy right now? You're not...
Penny Stocks · 5d ago
BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Appoints New Chairman of the Board
Investor Brand Network · 5d ago
BRIEF-Azurrx Biopharma Appoints President And CEO James Sapirstein As New Chairman Of The Board Of Directors
reuters.com · 5d ago
DJ AzurRx BioPharma Names CEO Sapirstein to Added Chairman Post >AZRX
Dow Jones · 5d ago
AzurRx BioPharma: Former Chmn Edward Borkowski to Continue as Lead Independent Director on Bd >AZRX
AzurRx BioPharma: Former Chmn Edward Borkowski to Continue as Lead Independent Director on Bd >AZRX
Dow Jones · 5d ago
AzurRx BioPharma Appoints Pres and CEO James Sapirstein as New Chmn of the Bd of Directors
AzurRx BioPharma Appoints Pres and CEO James Sapirstein as New Chmn of the Bd of Directors
Dow Jones · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AZRX. Analyze the recent business situations of AzurRx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AZRX stock price target is 4.500 with a high estimate of 7.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 4.19M
% Owned: 7.84%
Shares Outstanding: 53.42M
TypeInstitutionsShares
Increased
6
241.07K
New
7
192.96K
Decreased
2
56.21K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.05%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Independent Director
Edward Borkowski
President/Chief Executive Officer/Director
James Sapirstein
Chief Financial Officer
Daniel Schneiderman
Other
James Pennington
Independent Director
Charles Casamento
Independent Director
Gregory Oakes
Independent Director
Alastair Riddell
Independent Director
Vern Schramm
  • Dividends
  • Splits
  • Insider Activity
No Data
About AZRX
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Webull offers kinds of AzurRx BioPharma Inc stock information, including NASDAQ:AZRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AZRX stock methods without spending real money on the virtual paper trading platform.